Results 171 to 180 of about 626,377 (227)

Association of PCSK9 inhibitors versus statins with cancer incidence: a target trial emulation. [PDF]

Cardiooncology
Huang CH, Wang SI, Fan FS, Lu HJ, Wei JC.   +4 more
europepmc   +1 more source

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer.

JAMA Netw Open
Lu CA, Jiang C, Wang AZ, Zhang T.
europepmc   +1 more source

PCSK9 inhibitors and aging: Does chronological age matter? [PDF]

Atherosclerosis
Mouslmani MA, Nouri A, Damluji AA, Nanna MG.   +3 more
europepmc   +1 more source

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.

JAMA Netw Open
Kellogg C, Badillo Goicoechea E, Kim DD, Yaghi S, Chaturvedi S, Mehendale R, Orjuela K, Kass-Hout T, Morsi RZ, Morales J, Singh E, Jhaveri A, Prabhakaran S, Smith MM, Brorson JR, Golani S, Mazuera S, Kang R, Eltatawy A, Pillajo J, Siegler JE.   +20 more
europepmc   +1 more source

Cost-Effectiveness Analysis of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events in Italy. [PDF]

Clin Drug Investig
Musumeci G, Pradelli L, Lee K, Povero M.
europepmc   +1 more source

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective. [PDF]

Front Pharmacol
Hu D, Deng X, Feng M, Zhang X, He Q, Wang T, Feng Z.   +6 more
europepmc   +1 more source

Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease. [PDF]

Front Pharmacol
Zhang L, Ding Y, Zeng Y.
europepmc   +1 more source

The long-term effectiveness and tolerability of PCSK9 inhibitors in a large cardiovascular tertiary centre: A retrospective cohort analysis. [PDF]

Glob Cardiol Sci Pract
Tawil M, Omar F, Senanayake S, Cowdry M, Banya W, Neves E, Browne C, Mattar W, Grocott-Mason R, Barbir M.   +9 more
europepmc   +1 more source

PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies. [PDF]

Sci Rep
Singier A, Bénard-Laribière A, Jarne-Munoz A, Pariente A, Veyrac G, Bezin J.   +5 more
europepmc   +1 more source

PCSK9 Inhibitors or Cardiovascular Disease Inhibitors?

Journal of Cardiology & Cardiovascular Therapy, 2016
openaire   +1 more source